Overview

* AtriCure Q3 2025 revenue grows 15.8% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting improved financial performance

* Company raises full year 2025 revenue and adjusted EBITDA guidance

Outlook

* AtriCure ( ATRC ) expects full-year 2025 revenue forecast to $532 mln-$534 mln

* Company expects full-year 2025 Adjusted EBITDA of $55 mln-$57 mln

* AtriCure ( ATRC ) anticipates full-year 2025 adjusted loss per share of $0.23-$0.26

Result Drivers

* PRODUCT ADOPTION - Strong adoption of AtriClip, EnCompass, and cryoSPHERE devices drove revenue growth

* GEOGRAPHIC EXPANSION - International revenue increased by 22%, driven by broad growth across franchises and regions

* INNOVATION INVESTMENTS - Investments in product innovation and clinical science are building future growth catalysts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $134.30 $131.25

Revenue mln mln (9

Analysts

)

Q3 -$0.01 -$0.11

Adjusted (9

EPS Analysts

)

Q3 Beat $17.80 $11.65

Adjusted mln mln (7

EBITDA Analysts

)

Q3 Gross 75.50%

Margin

Q3 Gross $101.30

Profit mln

Q3 $200,000

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for AtriCure Inc ( ATRC ) is $51.50, about 29.2% above its October 28 closing price of $36.45

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)